- About
- Specialties & Areas of Expertise
- Locations & Patient Information
- Education & Research
- Accepted Insurance
- External Professional Relationships
Ted Skolarus, MD, MPH, FACS, is a urologic oncologist who specializes in the care of patients with prostate cancer, including caring for men with elevated prostate-specific antigen (PSA) levels and performing transperineal prostate biopsy.
Dr. Skolarus has fellowship training in urologic oncology, health services research and implementation science. His research aims to better understand and improve the care of men with prostate cancer.
With over 175 publications, Dr. Skolarus has expertise in quantitative and qualitative health services research, clinical trials and state-of-the-art implementation science methods to optimize best practice implementation in real-world clinical settings. In other words, he studies issues of cost, quality, and access to healthcare, and strategies to help get patients the right care in the right place at the right time.
Dr. Skolarus has presented at numerous regional, national and international meetings and organizations. He serves as faculty in the National Cancer Institute’s Training Institute for Dissemination and Implementation Research in Cancer, as well as a reviewer for the NIH Center for Scientific Review. His research has been funded by the National Cancer Institute, VA Health Services Research and Development Service (HSR&D), American Cancer Society, and the American Urological Association.
Dr. Skolarus has fellowship training in urologic oncology, health services research and implementation science. His research aims to better understand and improve the care of men with prostate cancer.
With over 175 publications, Dr. Skolarus has expertise in quantitative and qualitative health services research, clinical trials and state-of-the-art implementation science methods to optimize best practice implementation in real-world clinical settings. In other words, he studies issues of cost, quality, and access to healthcare, and strategies to help get patients the right care in the right place at the right time.
Dr. Skolarus has presented at numerous regional, national and international meetings and organizations. He serves as faculty in the National Cancer Institute’s Training Institute for Dissemination and Implementation Research in Cancer, as well as a reviewer for the NIH Center for Scientific Review. His research has been funded by the National Cancer Institute, VA Health Services Research and Development Service (HSR&D), American Cancer Society, and the American Urological Association.
Specialties
UChicago Medicine Duchossois Center for Advanced Medicine - Hyde Park5758 S. Maryland Ave., Chicago IL 606371-888-824-0200
Board Certifications
- Urology
Languages Spoken
- English
Medical Education
- Wayne State University School of Medicine
Internship
- Barnes Hosp. Washington University in St. Louis, Division of Urologic Surgery
Residency
- Barnes Hosp. Washington University in St. Louis, Division of Urologic Surgery
Fellowship
- University of Michigan Hospital, Ann Arbor
News & Research
Insurance
- Aetna Better Health *see insurance page
- Aetna HMO (specialists only)
- Aetna Medicare Advantage HMO & PPO
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS Medicare Advantage HMO & PPO
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Choice HMO (specialists only)
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If you have questions regarding your insurance benefits at UChicago Medicine, please contact our financial counseling team at OPSFinancialCounseling@uchospitals.edu.
UChicago Medicine is committed to fostering a corporate culture of ethical behavior and integrity in all matters related to compliance with the laws and regulations that govern the delivery of healthcare. This aspiration is central to supporting patient care, research, and teaching at UChicago Medicine.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.